Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hunting hidden pancreatic tumors: new tracer lights up insulinomas

NCT ID NCT07808879

Diagnosis Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Researchers are testing a new PET/CT imaging tracer designed to spot insulinomas, rare pancreatic tumors that cause dangerously low blood sugar. These tumors are often tiny and easy to miss on standard CT, ultrasound, or PET scans. The tracer targets a protein called GLP-1R that insulinoma cells carry in abundance, and a PEG6 modification aims to improve tumor uptake and image contrast. Twenty adults with suspected or confirmed insulinoma will each receive two scans within a week, one with the new tracer and one with an older version, then undergo surgery or biopsy so doctors can compare the scans against pathology results.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental PET imaging tracer called [68Ga]Ga-HBED-CC-PEG6-exendin-4
What this could lead to
If it works, this tracer could give doctors a sharper tool for finding small insulinomas that standard scans miss, which may help guide surgery.
What could go wrong
This is a small, early imaging study of 20 people at one hospital. The tracer may not improve detection over the older tracer, and results in this group may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18 and 70 years, male or female. 2. Clinically suspected insulinoma with biochemically proven endogenous hyperinsulinism. 3. Complete clinical information and conventional abdominal imaging data available. 4. Scheduled for pancreatic surgery or biopsy within 30 days after PET/CT examination for pathological confirmation. 5. Capable of completing two GLP-1R-targeted PET/CT scans within a 7-day interval. 6. Voluntarily provides written informed consent and cooperates with study procedures. Exclusion Criteria: 1. Pregnancy, suspected pregnancy, or lactating status. 2. Severe hepatic or renal dysfunction prohibiting radiotracer injection. 3. Known allergy or hypersensitivity to exendin-4, gallium-based tracers, or injection excipients. 4. Uncontrolled severe systemic diseases that preclude PET/CT acquisition.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insulinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic insulinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Insulinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.